Fig. 4
ARHGDIG-mediated IL4 release by HCC cells mediated MET formation and drug resistance. A The mRNA expression of candidate genes in Hep3B cells. NC: Hep3B cells received no treatment. Sora: Hep3B cells received treatment with sorafenib. n = 3. B The mRNA expression of IL4 in Hepa1-6 and Hep3B cells. n = 3. C The Western Blot assay of protein expressions of ARHGDIG and IL4 in Hep3B and Hepa1-6 cells. NC: no treatment. ARHGDIGknock: ARHGDIG knockdown in cells. Sora: treatment with sorafenib. Sora + ARHGDIGknock: ARHGDIG knocking cells received treatment with sorafenib. D ELISA detection of the IL4 concentration in the supernatant of Hepa1-6 and Hep3B cells. ELISA detection of the E MPO-DNA and F elastase concentration in the supernatant of M2-mBMDM and M2-THP-1 cells that were treated with media of HCC cell Hepa1-6 or Hep3B. G The intensity of SYTOX Green fluorescence in M2-mBMDM and M2-THP-1 cells that were treated with media of HCC cell Hepa1-6 or Hep3B. NC-CM: media of HCC cells. ARHGDIGknock: media of ARHGDIG-knockdown HCC cells. Sora: media of HCC cells receiving treatment with sorafenib. Sora + ARHGDIGknock: media of ARHGDIG-knockdown HCC cells receiving treatment with sorafenib. n = 6 (C–G). Statistical significance was calculated by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test (B, D–G). Data represent the mean ± standard deviation (SD) of ≥ three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001